These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Ridker PM Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021 [TBL] [Abstract][Full Text] [Related]
4. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Ridker PM; MacFadyen JG; Thuren T; Libby P Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417 [TBL] [Abstract][Full Text] [Related]
5. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview. Nidorf SM; Thompson PL Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286 [TBL] [Abstract][Full Text] [Related]
6. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease. Roman YM; Hernandez AV; White CM Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Ridker PM; Thuren T; Zalewski A; Libby P Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131 [TBL] [Abstract][Full Text] [Related]
9. Update on the Inflammatory Hypothesis of Coronary Artery Disease. Boland J; Long C Curr Cardiol Rep; 2021 Jan; 23(2):6. PubMed ID: 33409720 [TBL] [Abstract][Full Text] [Related]
10. [Anti-inflammatory therapy in cardiovascular disease; from hypothesis to future guideline?]. Hoogeveen RM; Stroes ESG; Cornel JH Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201620 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629 [TBL] [Abstract][Full Text] [Related]
16. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Everett BM; Donath MY; Pradhan AD; Thuren T; Pais P; Nicolau JC; Glynn RJ; Libby P; Ridker PM J Am Coll Cardiol; 2018 May; 71(21):2392-2401. PubMed ID: 29544870 [TBL] [Abstract][Full Text] [Related]
17. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease. Moreira DM; da Silva RL; Vieira JL; Fattah T; Lueneberg ME; Gottschall CA Am J Cardiovasc Drugs; 2015 Feb; 15(1):1-11. PubMed ID: 25369900 [TBL] [Abstract][Full Text] [Related]
18. An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk. Mohammadnia N; Opstal TSJ; El Messaoudi S; Bax WA; Cornel JH Clin Ther; 2023 Nov; 45(11):1055-1059. PubMed ID: 37716836 [TBL] [Abstract][Full Text] [Related]
19. Lessons learned from large Cardiovascular Outcome Trials targeting inflammation in cardiovascular disease (CANTOS, CIRT, COLCOT and LoDoCo2). Samuel M; Tardif JC Future Cardiol; 2021 May; 17(3):411-414. PubMed ID: 33687270 [No Abstract] [Full Text] [Related]